The pharmaceutical group Pfizer announced Tuesday a net loss of $1.65 billion in the fourth quarter of 2025, exacerbated by charges that nearly doubled year-on-year, but confirmed its targets for the 2026 fiscal year.

The Pfizer logo is seen outside the company's headquarters on August 8, 2025 in New York City. (File photo: AFP)

According to its press release, the US drugmaker recorded a total of $4.4 billion in charges, including asset impairments and lower financial returns, between October and December compared to $2.36 billion in the same period of 2024.